A Reappraisal of Thymosin Alpha1 in Cancer Therapy

Thymosin alphal (T alpha 1), an endogenous peptide first isolated from the thymic tissue in the mid-sixties, has gained considerable attention for its immunostimulatory activity that led to its application to diverse pathological conditions, including cancer. Studies in animal models and human patients have shown promising results in different types of malignancies, especially when T alpha 1 was used in combination with other chemo- and immune therapies. For this reason, the advancements in our knowledge on the adjuvant role of T alpha 1 have moved in parallel with the development of novel cancer therapies in a way that T alpha 1 was integrated to changing paradigms and protocols, and tested for increased efficacy and safety. Cancer immunotherapy has recently experienced a tremendous boost following the development and clinical application of immune checkpoint inhibitors. By unleashing the full potential of the adaptive immune response, checkpoint inhibitors were expected to be very effective against tumors, but it soon became clear that a widespread and successful application was not straightforward and shortcomings in efficacy and safety clearly emerged. This scenario led to the development of novel concepts in immunotherapy and the design of combination protocols to overcome these limitations, thus opening up novel opportunities for T alpha 1application. Herein, we summarize in a historical perspective the use of T alpha 1 in cancer, with particular reference to melanoma, hepatocellular carcinoma and lung cancer. We will discuss the current limitations of checkpoint inhibitors in clinical practice and the mechanisms at the basis of a potential application of T alpha 1in combination protocols.